Summit Creek Advisors LLC Sells 14,940 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Summit Creek Advisors LLC lowered its stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 6.5% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 214,996 shares of the medical instruments supplier’s stock after selling 14,940 shares during the quarter. LeMaitre Vascular makes up approximately 2.4% of Summit Creek Advisors LLC’s holdings, making the stock its 13th biggest holding. Summit Creek Advisors LLC owned about 0.96% of LeMaitre Vascular worth $17,690,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in LMAT. Van Hulzen Asset Management LLC grew its holdings in LeMaitre Vascular by 75.1% during the 4th quarter. Van Hulzen Asset Management LLC now owns 23,304 shares of the medical instruments supplier’s stock worth $1,323,000 after acquiring an additional 9,992 shares during the last quarter. Mesirow Institutional Investment Management Inc. bought a new stake in LeMaitre Vascular during the 4th quarter worth about $8,837,000. Johnson Investment Counsel Inc. grew its holdings in LeMaitre Vascular by 26.2% during the 4th quarter. Johnson Investment Counsel Inc. now owns 41,315 shares of the medical instruments supplier’s stock worth $2,345,000 after acquiring an additional 8,570 shares during the last quarter. Jump Financial LLC grew its holdings in LeMaitre Vascular by 25.2% during the 4th quarter. Jump Financial LLC now owns 18,342 shares of the medical instruments supplier’s stock worth $1,041,000 after acquiring an additional 3,692 shares during the last quarter. Finally, KLR Investment Advisors LLC bought a new stake in LeMaitre Vascular during the 4th quarter worth about $351,000. Institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Price Performance

Shares of NASDAQ:LMAT opened at $88.09 on Friday. The company has a market capitalization of $1.98 billion, a price-to-earnings ratio of 58.34, a P/E/G ratio of 2.38 and a beta of 0.89. The firm’s 50 day simple moving average is $85.47 and its 200 day simple moving average is $76.08. LeMaitre Vascular, Inc. has a fifty-two week low of $44.27 and a fifty-two week high of $92.90.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $0.52 earnings per share for the quarter, beating analysts’ consensus estimates of $0.47 by $0.05. The business had revenue of $55.85 million for the quarter, compared to the consensus estimate of $54.98 million. LeMaitre Vascular had a net margin of 18.33% and a return on equity of 12.41%. LeMaitre Vascular’s revenue for the quarter was up 11.4% on a year-over-year basis. During the same period last year, the company posted $0.37 EPS. Equities research analysts expect that LeMaitre Vascular, Inc. will post 1.85 earnings per share for the current year.

LeMaitre Vascular Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, August 29th. Investors of record on Thursday, August 15th were given a $0.16 dividend. The ex-dividend date was Thursday, August 15th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.73%. LeMaitre Vascular’s dividend payout ratio is 42.38%.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. StockNews.com downgraded shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Tuesday, August 27th. Roth Capital upgraded shares of LeMaitre Vascular to a “strong-buy” rating in a research report on Friday, May 31st. Roth Mkm restated a “buy” rating and set a $100.00 target price on shares of LeMaitre Vascular in a research report on Friday, May 31st. JMP Securities upped their target price on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the company a “market outperform” rating in a research report on Tuesday, August 20th. Finally, Barrington Research upped their target price on shares of LeMaitre Vascular from $79.00 to $92.00 and gave the company an “outperform” rating in a research report on Friday, August 2nd. Two research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, LeMaitre Vascular presently has a consensus rating of “Moderate Buy” and an average target price of $94.40.

Insider Activity at LeMaitre Vascular

In other LeMaitre Vascular news, Director David B. Roberts sold 3,063 shares of the firm’s stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $82.07, for a total transaction of $251,380.41. Following the sale, the director now directly owns 14,114 shares in the company, valued at approximately $1,158,335.98. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other LeMaitre Vascular news, CEO George W. Lemaitre sold 27,030 shares of the firm’s stock in a transaction that occurred on Monday, July 15th. The shares were sold at an average price of $86.27, for a total transaction of $2,331,878.10. Following the sale, the chief executive officer now directly owns 1,958,328 shares in the company, valued at approximately $168,944,956.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director David B. Roberts sold 3,063 shares of the firm’s stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $82.07, for a total transaction of $251,380.41. Following the sale, the director now owns 14,114 shares in the company, valued at $1,158,335.98. The disclosure for this sale can be found here. Insiders have sold 43,251 shares of company stock worth $3,714,994 in the last ninety days. Company insiders own 10.79% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.